Study of Everolimus With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma

Phase 2 Completed 70 enrolled SCRI Development Innovations, LLC Novartis · collab

NaSingle-groupOpen-labelTreatment

Summary

Based on data demonstrating synergy between paclitaxel and mammalian target of rapamycin (mTOR) inhibition, the investigators propose that the addition of everolimus to paclitaxel with carboplatin should lead to improvements in efficacy as measured by progression-free survival and response rate.

Timeline

Start: 2010-02
Primary completion: 2012-02
Completion: 2013-08

Publications

Results Hauke RJ, Infante JR, Rubin MS, Shih KC, Arrowsmith ER, Hainsworth JD. Everolimus in combination with paclitaxel and carboplatin in patients with metastatic melanoma: a phase II trial of the Sarah Cannon Research Institute Oncology Research Consortium. Melanoma Res. 2013 Dec;23(6):468-73. doi: 10.1097/CMR.0000000000000014.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Carboplatin	Small molecule	6 unknown	Intravenous
Subject	Everolimus	Small molecule	5 mg	Oral
Subject	Paclitaxel	Small molecule	175 mg/m2	Intravenous

Study of Everolimus With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma

Summary

Timeline

Publications

Drugs

Indications